首页 产业/市场分类 出版商一览 Email 通知 GII媒体代理会议 公司简介 联络我们
- English Japanese Korean
首页 > 市场调查报告书 > 制药 > 规章 > 中国的医疗改革与IVD，医疗设备，对医药品市场的影响
产业/市场分类
制药 (4823)
肥胖症治疗 (44)
非专利药 (129)
疫苗 (181)
神经疾病 (172)
骨头疾病治疗 (37)
动物用医药 (18)
处方药 (156)
规章 (130)
感染疾病 (347)
精神病 (85)
制药企业 (526)
糖尿病 (191)
癌症 (903)
药物开发 (1458)
DDS (182)
OTC 非处方药 (150)
市场调查报告书

中国的医疗改革与IVD，医疗设备，对医药品市场的影响

China Healthcare Reform and Its Impact on IVD, Medical Device and Pharmaceutical Markets

出版商 Kalorama Information
出版日期 2011年10月 商品编码 221330
内容信息 英文 167 Pages
价格
US $ 3500 PDF by E-mail (Single User License)
US $ 4750 PDF by E-mail (Departmental License)
US $ 7000 PDF by E-mail (Global Site License)


中国的医疗改革与IVD，医疗设备，对医药品市场的影响 是由出版商Kalorama Information在2011年10月所出版的。 这份英文市场调查报告书包含167 Pages 价格从美金3500起跳。

简介

中国急速的经济发展以及1997年以后中央政府的许多改革，对该国国内医疗服务市场与医药品，医疗设备，体外诊断(IVD)市场产生很大的影响。

本报告提供中国的医疗制度的概要与制度改革的背景，IVD产品，医疗设备，医药品市场趋势，各地区分析汇整，为您概述为以下内容。

第1章 摘要整理

第2章 简介与主要的指标和改革的需求

  • 简介
  • 医疗辅助员和Rural Cooperative Medical Scheme
  • 中国的经济改革对医疗的影响
  • Rural Cooperative Medical Scheme与政府改革的再承诺
  • 医疗改革

第3章 中国的医疗市场改革与所形成的地方，城市，地区，省的市场

  • 简介
  • 2009～2011年的医疗改革
  • 基层层级的医疗改革
  • 海外医疗产品供应商渗透中国市场

第4章 中国的诊断药:到2015年的市场的机会与课题

  • 简介
  • 中国IVD市场上需求面促进因素
    • 糖尿病
    • 癌症
    • 过敏
    • 感染病
  • 医疗制度/改革的供应方面的促进因素
    • 诊疗部门实验室
    • 自我检验
    • 医院·民间检验所
    • 研究·技术部门
  • 市场规模与预测
  • 市场分布与产业趋势
    • 中国国内的IVD产业
  • 相关法规

第5章 中国的医疗设备:到2015年的市场的机会与课题

  • 简介
  • 中国医疗设备市场需求面促进因素
    • 癌症
    • 心血管疾病
    • 高龄化
  • 医疗制度/改革:供应方面的促进因素
    • 医院
    • 特殊治疗诊所
    • 公共诊所，健康中心，"基层"医疗机关
  • 市场规模与预测
  • 市场分布与产业趋势
    • 中国国内的IVD产业
  • 相关法规
    • 制造企业的认证
    • 医疗程序和和报销的费用削减
    • 设备认证

第6章 中国的医药品:到2015年的市场的机会与课题

  • 简介
  • 中国医药品市场上需求面促进因素
    • 糖尿病
    • 高血压·心脏病
    • 癌症
    • 感染病
    • 自我医疗
  • 供应方面的促进因素与市场流通管道
    • 院内药物部
    • 零售药局
    • 其他的商业流通管道:量贩店，邮购，线上
  • 市场规模与预测
  • 市场分布与产业趋势
    • "大制药公司"
    • 中国国内的医药品产业
  • 相关法规
    • 制造企业的认证
    • 制造商层级的药价管理
    • 药局等级的药价管理
    • 药物核准
    • 智能财产权保护

第7章 结论

图表

目录

Abstract

China's rapid economic development and the numerous steps of reform undertaken by the Chinese central government since 1997 have had clear and observable effects upon China's total healthcare services market and its product markets for pharmaceuticals, medical devices, and in vitro diagnostics (IVD). This progress has been augmented by a Reform program in 2009, which includes increased funding to improve services.

What are the workings of China's healthcare system? How much progress has been made towards the promised vision of the CPCC in 2008 to provide “convenient and affordable access” to its people? What are the effects on foreign companies seeking to benefit from an increase in healthcare-related funding? Where are the best opportunities in China for marketers? Kalorama analyst Emil Salazar focuses on these questions and more.

The report contains a comprehensive overview of the Chinese healthcare system with important data for marketers to China. It discusses healthcare reform plans and where funds were spent. It also describes the role foreign companies play.

As part of its analysis, the report includes the following information:

  • Statistics on Chinese Hospitals, Community Health Centers and Clinics
  • Top and Bottom City Markets for Urban Healthcare
  • Top and Bottom Rural Regions
  • Challenges for Foreign-Owned MNCs in China
  • Government Healthcare Spending
  • Foreign-Invested Manufacturing Enterprises in China
  • Share of Government Funded Healthcare vs. Out of Pocket
  • Domestic Healthcare Industries
  • Population and Age Statistics
  • Incidence Rates for Infectious Diseases
  • Cancer Rates in China
  • Regulation of Drugs and Devices in China
  • U.S. Product Exports to China
  • Key Analyst Conclusions

In addition to providing useful background information and a thorough analysis of China's healthcare changes, the report provides data for business planning.

It also takes a look at the status and forecast of the three key healthcare markets in China:

  • The Chinese Market for IVD products
  • Regional Breakout of the Chinese IVD Market (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
  • The Chinese Market for Medical Device Products
  • Regional Breakout of the Chinese Medical Device Market (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
  • Segment Breakout of the Chinese Medical Device Market (Surgical Instrument, Disposable, Patient Monitoring, IVD, Imaging, Orthopedic, Other)
  • The Chinese Market for Pharmaceutical Products
  • Regional Breakout of the Pharmaceutical Market (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
  • Segment Breakout of the Pharmaceutical Market (Cardiovascular, Gastrointestinal, Anti-Infectives, Neurotherapeutics, Oncology, Respiratory, Other)

This essential resource for anyone marketing a healthcare product to China was constructed using a combination of primary and secondary sources. Corporate reports, trade publications government information and medical journals, previous market research studies conducted by Kalorama and other sources were used. In some cases, interviews were used to determine forecasts and key trends.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Healthcare in China
  • Healthcare Reform and Market Impact
    • Rural Healthcare Market in Era of Reform
    • Urban Healthcare Market in Era of Reform
    • China's IVD Market in an Era of Reform
    • China's Medical Devices Market in an Era of Reform
    • China's Pharmaceuticals Market in an Era of Reform
  • Major Findings

CHAPTER TWO: HEALTHCARE IN CHINA - PRIMARY INDICATORS AND A NEED FOR REFORM

  • Introduction
  • Barefoot Doctors and the Rural Cooperative Medical Scheme (RCMS)
  • China's Economic Reform Impacts Healthcare
  • New Rural Cooperative Medical Scheme (NRCMS) and Government Recommitment to Reform
  • China on the Eve of Contemporary Healthcare Reform

CHAPTER THREE: CHINA'S “REFORM” HEALTHCARE MARKET AND ITS SHAPING OF RURAL, URBAN, REGIONAL AND PROVINCIAL MARKETS

  • Introduction
  • China's 2009-2011 Healthcare Reform in Its Main Features and Provisions
  • Healthcare Reform on the “Grassroots” Level - The Many Chinas in Focus
    • The Contemporary Rural Healthcare Market in China - Major Regions, Institutions and Landscape
    • Rural China Healthcare Market from the NRCMS to the End of Healthcare Reform under the 12th Five-Year Plan (2004-2015) - Historical and Projected Market Sizes and Segmentation
    • Urban Healthcare Markets in China and their Trajectory through Reform (2004-2015)
  • Foreign Medical Product Suppliers Penetrate the Chinese Market

CHAPTER FOUR: DIAGNOSTICS IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015

  • Introduction
  • Demand-Side Drivers in the Chinese IVD Market
    • Diabetes
    • Cancer
    • Allergy
    • Infectious Disease
  • Healthcare System/ Reform Supply-Side Drivers
    • Physician Office Laboratories (POL
    • Self-Testing
    • Hospital and Private Laboratories
    • Research and Technology Sector
  • Market Size and Projections
  • Market Distribution and The State of The Industry
    • Domestic Chinese IVD Industry
  • Regulation

CHAPTER FIVE: MEDICAL DEVICES IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015

  • Introduction
  • Demand-Side Drivers in the Chinese Medical Device Market
    • Cancer
    • Cardiovascular Diseases
    • Aging
  • Healthcare System/Reform - Supply-Side Drivers
    • Hospitals
    • Specialty Treatment Clinics
    • Public Clinics, Health Centers and “Grass Roots” Medical Institutions
  • Market Size and Projections
  • Market Distribution and the State of the Industry
    • Foreign Manufacturers
    • Domestic Chinese IVD Industry
  • Regulation
    • Manufacturing Enterprise Approvals
    • Cost Controls for Medical Procedures and Reimbursements
    • Device Approval

CHAPTER SIX: PHARMACEUTICALS IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015

  • Introduction
  • Demand-Side Drivers in the Chinese Pharmaceuticals Market
    • Diabetes
    • Hypertension and Heart Disease
    • Cancer
    • Infectious Diseases
    • Self-Medication
  • Supply-Side Drivers (Healthcare Reform) and Market Channels
    • Hospital Pharmacies
    • Retail Pharmacies
    • Other Commercial Channels - Mass Merchants, Mail Order and Online
  • Market Size and Projections

MARKET DISTRIBUTION AND THE STATE OF THE INDUSTRY

  • “Big Pharma” - western MNCs in China
  • Domestic Chinese Pharma Industry

REGULATION

  • Manufacturing Enterprise Approvals
  • Pricing Controls at Manfacturer-Level
  • Pricing Controls at Pharmacy-Level
  • Drug Approval
  • Intellectual Property Protection (IPP)

CHAPTER SEVEN: CONCLUSIONS

  • Conclusion One
  • Conclusion Two
  • Conclusion Three
  • Conclusion Four
  • Conclusion Five
  • Conclusion Six
  • Conclusion Seven

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: Government-Run Urban Health Insurance Programs in China
  • Figure 1-1: Chinese Healthcare Reform Government Funding Breakdown (2009-2011)
  • Figure 1-2: Rural and Urban China Healthcare Market (Insurance and Out-of-Pocket Payments) (2004-2015) (billion yuan)
  • Figure 1-3: IVD, Pharmaceuticals and Medical Devices Markets in China (2004-2015) (billions $)

CHAPTER TWO: HEALTHCARE IN CHINA - PRIMARY INDICATORS AND A NEED FOR REFORM

  • Figure 2-1: Chinese National Population (% Urban/Rural)
  • Figure 2-2: Chinese Government Health Expenditures (in billion yuan and % of total health expenditures) (1980-2009)
  • Figure 2-3: Average Inpatient Visit Costs and Bed Utilization at Chinese Public Hospitals (1985-2010)
  • Figure 2-4: Gross National Income (GNI) Per Capita - China and OECD Member Country Average (1980-2009)
  • Figure 2-5: Chinese Bureaucratic and Market Divisions (East, Middle, West China)
  • Figure 2-6: Private Hospitals in China by Region (East / Middle / West) (2010)
  • Figure 2-7: Number of Private and Public Hospitals in China (1980-2010)
  • Figure 2-8: Income Sources for Government-Run Hospitals (%)
  • Figure 2-9: New Rural Cooperative Medical Scheme Enrollment (2004-2010)
  • Table 2-1: Government-Run Urban Health Insurance Programs in China
  • Figure 2-10: Government Health Insurance Coverage (2003 and 2008)
  • Figure 2-11: Hospital Visits in China (millions) (1995-2010)
  • Table 2-2: Government Healthcare Expenditure and GDP Growth Rates (China and Selected Comparison Countries; 2000-2008
  • Figure 2-12: Chinese Population by Age (Total; 1990/2000/2009) (%)

CHAPTER THREE: CHINA'S “REFORM” HEALTHCARE MARKET AND ITS SHAPING OF RURAL, URBAN, REGIONAL AND PROVINCIAL MARKETS

  • Figure 3-1: Chinese Healthcare Reform Government Funding Breakdown (2009-2011)
  • Figure 3-2: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality (2010)
    • Rural China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance Expenditures) (2004-2010) (billion yuan)
  • Table 3-1: Rural China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance Expenditures) (2004-2010) (billion yuan)
  • Figure 3-4: Regional Shares of Reimbursement Funds under NRCMS (2010) (East/Middle/West China) (%)
  • Figure 3-5: Rural China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance Expenditures) (2010-2015 Projection) (billion yuan)
  • Table 3-2: Rural China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance Expenditures) (2010-2015 Projection) (billion yuan)
  • Table 3-3: Top and Bottom Five Provincial Markets for Rural Healthcare by Gain and Loss in National Market Share (2010-2015)
  • Figure 3-6: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality (2010)
  • Figure 3-7: Outpatient Visits in the Urban Healthcare Market, 2010 (Hospitals, Community Health Centers, Community Health Stations, Clinics, Other) (millions of visits)
  • Figure 3-8: Composition of Chinese Hospital Sector by Number of Beds, 2000-2010 (percent)
  • Figure 3-9: Urban China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance Expenditures) (2004-2010) (billion yuan)
  • Table 3-4: Urban China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance Expenditures) (2004-2010) (billion yuan)
  • Figure 3-10: Top and Bottom Five Provincial Markets for Urban Healthcare by Gain and Loss in National Market Share (2010-2015)
  • Figure 3-11: U.S. Medical Product Export Growth to China (1990-2010)
  • Figure 3-12: Total U.S.-EU Exports to China - Pharmaceutical Products and Medical Devices (2002-2010) (millions of U.S. dollars)
  • Figure 3-13: Inbound Foreign Direct Investment in Medical Product Manufacturing in China (2002-2010)
  • Figure 3-14: Foreign-Invested Manufacturing Enterprises in China (1980-2010)
  • Figure 3-15: Foreign-Invested Manufacturing Enterprises in China by Province/Municipality (1995-2010)

CHAPTER FOUR: DIAGNOSTICS IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015

  • Figure 4-1: Chronic Disease Morbidity Rates in Urban China - Hypertension, Diabetes, Cerebrovascular Disease (Stroke), Chronic Obstructive Pulmonary Disease, Heart Disease (per thousand [0/00]) (2003/2008)
  • Figure 4-2: Chronic Disease Morbidity Rates in Rural China - Hypertension, Diabetes, Stroke, Chronic Obstructive Pulmonary Disease, Heart Disease (2003/2008)
  • Figure 4-3: Cancer Mortality Rates in China - Lung, Liver, Stomach, Esophageal, Colon, Leukemia, Brain, Breast, Pancreatic (Per 100,000) (2005)
  • Table 4-1: Incidence Rates for Top Ten Notifiable Infectious Diseases (2010)
  • Table 4-2: Selected Preventative Medicine Opportunities
  • Table 4-3: Selected Disease Prevention Programs in China's Healthcare Reform (2009-2011)
  • Table 4-4: Clinical Labs by Instrumentation Type in BRIC Countries
  • Figure 4-4: Chinese Market for IVD Reagents ($ millions) (2004-2015)
  • Figure 4-5: Regional Market Divisions for Medical Products in China (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
  • Table 4-5: Regional Markets for IVD Products in China (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern), 2010-2015
  • Table 4-6: IVD Market Segmentation (2009) (% of sales)
  • Table 4-7: IVD Market Shares by Company (2009) (%)
  • Table 4-8: BRIC IVD Market Comparison (2010) ($ millions)
  • Table 4-9: Selected Made-in-China Lab Supplies
  • Table 4-10: Selected IVD Manufacturers in China
  • Figure 4-6: IVD Product Registration and Regulatory Flowchart

CHAPTER FIVE: MEDICAL DEVICES IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015

  • Figure 5-1: Cancer Mortality Rates in China - Lung, Liver, Stomach, Esophageal, Colon, Leukemia, Brain, Breast, Pancreatic (Per 100,000) (2005)
  • Figure 5-2: Chinese Population by Age (Total; 1990/2000/2009) (%)
  • Figure 5-3: Composition of Chinese Hospital Sector by Number of Beds, 2000-2010
  • Figure 5-4: Compositional Changes in the Hospital Sector - Private, Third-Level and Specialty Hospitals (2005-2010)
  • Figure 5-5: Chinese Market for Medical Devices ($ billions) (2004-2015)
  • Figure 5-6: Regional Market Divisions for Medical Products in China (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
  • Table 5-1: Regional Markets for Medical Devices in China, $ billions 2010 and 2015 (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
  • Figure 5-7: China Medical Device Market - Product Segment Shares Percent, 2010 (Surgical Instrument, Disposable, Patient Monitoring, IVD, Imaging, Orthopedic, Other)
  • Figure 5-8: Foreign-Invested Manufacturing Enterprises in China (1980-2010)
  • Figure 5-9: Medical Device Registration and Approval Flowchart

CHAPTER SIX: PHARMACEUTICALS IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015

  • Figure 6-1: Chronic Disease Morbidity Rates in Urban China - Hypertension, Diabetes, Cerebrovascular Disease (Stroke), Chronic Obstructive Pulmonary Disease, Heart Disease (per thousand [0/00]) (2003/2008)
  • Figure 6-2: Cancer Mortality Rates in China - Lung, Liver, Stomach, Esophageal, Colon, Leukemia, Brain, Breast, Pancreatic (Per 100,000) (2005)
  • Table 6-1: Incidence Rates for Top Ten Notifiable Infectious Diseases (2010)
  • Figure 6-3: Chinese Market for Pharmaceuticals (incl. Hong Kong) ($ billions) (2004-2015)
  • Figure 6-4: Regional Market Divisions for Medical Products in China (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
  • Table 6-2: Regional Markets for Pharmaceuticals in China, $ billions, 2010-2015 (Eastern , Northern , Central , Southern , Northeastern , Southwestern , Northwestern )
  • Figure 6-5: China Pharmaceutical Market - Patented Prescription, Generics, OTC Market Shares (%) (2010)
  • Table 6-3: China Pharmaceutical Market (Patented Prescription and Generics only) by Product Segment, 2010 and 2015 (Cardiovascular, Gastrointestinal, Anti-Infectives, Neurotherapetuics, Oncology, Respiratory, Other)
  • Figure 6-6: Foreign-Invested Manufacturing Enterprises in China (1980-2010)
  • Table 6-4: Leading Medicinal Manufacturers in China (2009) (%, National Share of Aggregate Pharma/TCM/Nutritional Market)
  • Table 6-5: Pharmaceutical Price Cuts (2000-2010)
  • Figure 6-7: Pharmaceutical Approval and Regulatory Flowchart

Press Release

中国准都市医药品·医疗机器的市场机会

2011年11月28日

Global Information, Inc.已开始销售Kalorama Information所发行的报告书「China Healthcare Reform and Its Impact on IVD, Medical Device and Pharmaceutical Markets (中国的医疗改革与IVD，医疗设备，对医药品市场的影响)」

医药品、医疗机器、诊断药的行销企业，有在中国的准都市找到最大成长机会的可能性。

依据该报告书，中国医疗市场在居住都市的人口比例，从2000年到2010年间从36％增加到50％。

主要的医疗市场集中在上海、香港、北京及广州大都市圈的周遭。这样的都市医疗市场，对各种医药品及医疗机器有著高需求。由于中国全国都市化，沿岸地区和中央、西部的准都市，亦衍生出对医药品和医疗机器的需求。

中国都市的经济发展和都市的人口移动，支持著都市医疗市场的成长。

农村的居民，也有希望在都市医院接受外来专业·住院治疗的倾向。

中国2010年的都市医疗市场（包括香港）约为1兆2,400亿元（1,832亿美元）规模，是农村医疗市场的3倍以上。

继续优先提高农村医疗，中国政府必须管理都市医疗系统，提供资金。都市医疗系统须有更多样化的高额投资，农村医疗亦有同样覆盖范围的问题。

最近已扩展的国民健康计划，农村加入者的总额与城市加入者相较，归还5倍以上。

本报告书亦依地区分析主要的都市医疗市场。

分析家Emil Salazar叙述：「中国西部的成都、重庆、及中央部的郑州，武汉，已经受到MNC R&D投资的恩惠。」。「这些都市都是医疗产品销售的目的地，亦是医药品和IVD试剂及医疗用品地方·地区流通网路理想的中心据点。」

中国的西南与中央部医药品及医疗机器市场，在新兴都市强烈需求的支持下，预测今后4年将最大幅成长。

本报告书针对从2004年开始到2015年之IVD、医药品、医疗机器依地区提供分析。
Back to Top